South Korea Epigenetics Market Insight
Published: 18 July 2026 | Report Format: Electronic (PDF) | Author: Sanket and Pranali
South Korea Epigenetics market is anticipated to grow at a compound annual growth rate of roughly 10.09% in South Korea due to the coauntry's growing chronic disease prevalence, and sophisticated research infrastructure.
South Korea Epigenetics Market Insights Forecasts to 2035
- The South Korea Epigenetics Market Size Was Estimated USD 210.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 10.09% from 2025 to 2035
- The South Korea Epigenetics Market Size is Expected to rise around USD 550.2 Million by 2035
Notable Insights for the South Korea Epigenetics Market
- Reagents are the largest revenue-generating segment in the South Korean epigenetics market, according to product type segmentation. Enzymes, kits, instruments, and services are all constantly expanding, with services showing the greatest growth rate.
- According to application segmentation, the market is dominated by cancer therapy, which is followed by neurological and genetic disorders. As research into the epigenetic processes of heart disease and metabolic disorders grows, cardiovascular applications are expanding quickly.
- South Korea is a busy place for epigenetics research in Asia. The government is helping by giving a lot of money. KRW 4.5 billion. To Ewha Womans University for research.
- The epigenetics market in South Korea is going to be big by 2030. It will be worth about USD 1,147.3 million. The epigenetics market was worth about USD 358.6 million in 2023.
Download the eBook (ToC)
Why Buy This Report
- This report gives you all the information you need to know about the South Korea Epigenetics Market. It tells you about the past, present and future of the market. This helps you make investment decisions.
- The report also tells you about the parts of the South Korea Epigenetics Market. This helps you understand what is happening in the market and where you can make money.
- The report gives you information about the companies in the South Korea Epigenetics Market. This helps you understand who is doing what and where you can fit in.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea epigenetics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Epigenetics Market
- Genomictree Inc.
- Illumina Korea
- Thermo Fisher Scientific Korea
- Roche Korea
- Abcam Korea
- Active Motif Korea
- Agilent Technologies Korea
- Qiagen Korea
- Novartis Korea
- Eisai Korea
Recent Developments:
- In June 2025, following advancements in the commercialization of its EarlyTect®-C DNA methylation-based colorectal cancer diagnostic, it received a milestone payment, marking a significant milestone in its partnership with Geneis Beijing in China.
- In February 2025, improved epigenetics research workflow solutions, such as sophisticated sequencing preparation and methylation analysis reagents, were introduced to assist South Korean biomarker discovery and oncology labs.
Market Segmentation:
South Korea Epigenetics Market, By Product Type
- Reagents
- Kits
- Instruments
- Enzymes
- Services
South Korea Epigenetics Market, By Technology
- CRISPR
- DNA Methylation
- Histone Modification
- Non-coding RNA
South Korea Epigenetics Market, By Application
- Cancer Treatment
- Genetic Diseases
- Neurological Disorders
- Cardiovascular Disorders
Expert Views:
The market of epigenetics of South Korea is going to enjoy steady growth during the forecast period due to increased development in precision medicines, high levels of government funding, and growing investments in genomics and cancer studies. The innovations in sequencing techniques, biomarkers discoveries, and epigenetics therapeutics will facilitate the process. Biotech companies' partnerships with research organizations and pharmaceuticals will contribute to market competitiveness till 2035.
Author: Sanket and Pranali By Decisions Advisors and Consulting